Reach Us +1-218-451-2974


Alzheimer′s Drug Discovery: Targeting Astrocyte Synaptic Glutamate Uptake | 84199
ISSN: 2161-0460

Journal of Alzheimers Disease & Parkinsonism
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Recommended Conferences
Google scholar citation report
Citations : 2275

Journal of Alzheimers Disease & Parkinsonism received 2275 citations as per google scholar report

Journal of Alzheimers Disease & Parkinsonism peer review process verified at publons
Indexed In
  • Index Copernicus
  • Google Scholar
  • Sherpa Romeo
  • Open J Gate
  • Genamics JournalSeek
  • Academic Keys
  • JournalTOCs
  • China National Knowledge Infrastructure (CNKI)
  • Electronic Journals Library
  • RefSeek
  • Hamdard University
  • OCLC- WorldCat
  • SWB online catalog
  • Virtual Library of Biology (vifabio)
  • Publons
  • Geneva Foundation for Medical Education and Research
  • Euro Pub
Share This Page

Alzheimer′s drug discovery: Targeting astrocyte synaptic glutamate uptake

10th International Conference on Vascular Dementia

Markku Kurkinen

Wayne State University, USA

Keynote: J Alzheimers Dis Parkinsonism

DOI: 10.4172/2161-0460-C1-035

According to the amyloid hypothesis, Alzheimer dementia begins in the brain with Aβ peptides accumulation and amyloid formation. However, clinical drug trials targeting Aβ peptides and brain amyloid have failed to help anybody living with Alzheimer. Instead of repeating similar trials and errors of 25 years, we have to discover novel drug targets and better our research to prevent and treat Alzheimer. Glutamate is the synaptic signaling molecule of neurons. As soon as the glutamate signaling starts it is stopped in 0.1-2 ms by astrocytes, which take up and clear glutamate from synapses. This prevents glutamate neurotoxicity causing synapse loss and neuron cell death. Astrocytes make EAAT2 (excitatory amino acid transporter-2), the major glutamate transporter and 1% of brain protein. In Alzheimer dementia, astrocytes are impaired in glutamate uptake. In experimental mouse models of Alzheimer, increasing EAAT2 expression slows dementia progression. To discover drugs that can activate EAAT2 in glutamate uptake; we describe a simple assay that targets the EAAT2 protein reconstituted in liposomes and measures glutamate uptake with Oxonol VI red light. By directly targeting the EAAT2 protein, the assay should limit ‘offtargeting’ of drugs and adverse events, which are the main problems in Alzheimer’s drug discovery and clinical development. We may have to screen a million or more drugs, chemical compounds and natural products, before we find what we are looking for. We believe our drug assay of liposome glutamate uptake, in a high-throughput screening (HTS) format, can do exactly that. For efficacy, specificity and safety, the EAAT2 activating drugs are studied in an experimental C. elegans model of Alzheimer.

Markku Kurkinen has completed his PhD in 1979 at University of Helsinki, Finland and Post-doctoral studies from 1980-1983 at Imperial Cancer Research Fund, Mill Hill, London, UK. He was an Assistant Professor from 1984-1986 at Rutgers Medical School, Piscataway, New Jersey, USA; Associate Professor from 1986-1992, and Division Chief, Connective Tissue Research, Robert Wood Johnson Medical School, Piscataway, New Jersey, USA. He is a Professor at Wayne State University School of Medicine, Detroit, Michigan, USA. He has published more than 100 papers, reviews and book chapters.
Email:[email protected]